Amphastar Pharmaceuticals (AMPH) Competitors

$21.78 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$21.38 -0.40 (-1.81%)

As of 07:11 AM Eastern

AMPH vs. BEAM, DYN, RLAY, ARQT, and GPCR

Should you buy Amphastar Pharmaceuticals stock or one of its competitors? MarketBeat compares Amphastar Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amphastar Pharmaceuticals include Beam Therapeutics (BEAM), Dyne Therapeutics (DYN), Relay Therapeutics (RLAY), Arcutis Biotherapeutics (ARQT), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Amphastar Pharmaceuticals compare to Beam Therapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Beam Therapeutics' net margin of -39.66%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Amphastar Pharmaceuticals currently has a consensus target price of $24.00, indicating a potential upside of 10.19%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 34.53%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

Amphastar Pharmaceuticals has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$720.53M	1.33	$98.09M	$1.66	13.12
Beam Therapeutics	$139.74M	25.63	-$79.99M	-$0.68	N/A

In the previous week, Beam Therapeutics had 4 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 6 mentions for Beam Therapeutics and 2 mentions for Amphastar Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.73 beat Amphastar Pharmaceuticals' score of -0.28 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Neutral
Beam Therapeutics	Positive

Summary

Beam Therapeutics beats Amphastar Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Dyne Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

In the previous week, Dyne Therapeutics had 11 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 13 mentions for Dyne Therapeutics and 2 mentions for Amphastar Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.02 beat Amphastar Pharmaceuticals' score of -0.28 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dyne Therapeutics	Neutral
Amphastar Pharmaceuticals	Neutral

Dyne Therapeutics presently has a consensus target price of $34.17, indicating a potential upside of 63.16%. Amphastar Pharmaceuticals has a consensus target price of $24.00, indicating a potential upside of 10.19%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Dyne Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Amphastar Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Amphastar Pharmaceuticals	$720.53M	1.33	$98.09M	$1.66	13.12

Summary

Dyne Therapeutics and Amphastar Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, Relay Therapeutics had 4 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 6 mentions for Relay Therapeutics and 2 mentions for Amphastar Pharmaceuticals. Relay Therapeutics' average media sentiment score of 0.18 beat Amphastar Pharmaceuticals' score of -0.28 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relay Therapeutics	Neutral
Amphastar Pharmaceuticals	Neutral

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Relay Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Amphastar Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	231.66	-$276.48M	-$1.57	N/A
Amphastar Pharmaceuticals	$720.53M	1.33	$98.09M	$1.66	13.12

Relay Therapeutics currently has a consensus price target of $23.30, indicating a potential upside of 25.54%. Amphastar Pharmaceuticals has a consensus price target of $24.00, indicating a potential upside of 10.19%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Relay Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Relay Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Summary

Relay Therapeutics beats Amphastar Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 2 mentions for Amphastar Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Amphastar Pharmaceuticals' score of -0.28 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Neutral
Arcutis Biotherapeutics	Positive

Amphastar Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$720.53M	1.33	$98.09M	$1.66	13.12
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Amphastar Pharmaceuticals currently has a consensus price target of $24.00, indicating a potential upside of 10.19%. Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 25.93%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Amphastar Pharmaceuticals beats Arcutis Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Structure Therapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Structure Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Structure Therapeutics	N/A	-24.91%	-23.67%

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 2 mentions for Amphastar Pharmaceuticals and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Amphastar Pharmaceuticals' score of -0.28 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Neutral
Structure Therapeutics	Very Positive

Amphastar Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, meaning that its share price is 235% less volatile than the broader market.

Amphastar Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$720.53M	1.33	$98.09M	$1.66	13.12
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Amphastar Pharmaceuticals presently has a consensus price target of $24.00, indicating a potential upside of 10.19%. Structure Therapeutics has a consensus price target of $110.55, indicating a potential upside of 122.38%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Amphastar Pharmaceuticals beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPH vs. The Competition

Export

Metric	Amphastar Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$960.35M	$6.01B	$6.83B	$12.17B
Dividend Yield	N/A	0.63%	2.67%	6.11%
P/E Ratio	13.12	9.23	25.89	24.17
Price / Sales	1.33	23.94	545.01	100.37
Price / Cash	5.12	9.05	29.09	36.93
Price / Book	1.27	4.33	10.75	6.38
Net Income	$98.09M	$99.67M	$3.58B	$337.00M
7 Day Performance	18.82%	6.67%	1.90%	-0.23%
1 Month Performance	15.54%	3.85%	-0.26%	-1.40%
1 Year Performance	-5.63%	130.64%	34.39%	27.76%

Amphastar Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPH Amphastar Pharmaceuticals	2.643 of 5 stars	$21.78 flat	$24.00 +10.2%	-5.6%	$960.35M	$720.53M	13.12	1,976
BEAM Beam Therapeutics	2.1954 of 5 stars	$33.20 -6.6%	$46.83 +41.1%	+107.2%	$3.42B	$164.01M	N/A	510
DYN Dyne Therapeutics	2.8148 of 5 stars	$20.26 -2.9%	$33.85 +67.1%	+118.8%	$3.35B	N/A	N/A	100	Analyst Forecast Insider Trade
RLAY Relay Therapeutics	2.9413 of 5 stars	$17.44 +0.9%	$23.30 +33.6%	+462.4%	$3.34B	$15.35M	N/A	330	Gap Down
ARQT Arcutis Biotherapeutics	3.3247 of 5 stars	$26.27 -1.5%	$34.00 +29.4%	+96.5%	$3.29B	$376.07M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMPH) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. BEAM, DYN, RLAY, ARQT, and GPCR

How does Amphastar Pharmaceuticals compare to Beam Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Relay Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. BEAM, DYN, RLAY, ARQT, and GPCR

How does Amphastar Pharmaceuticals compare to Beam Therapeutics?

Is AMPH or BEAM more profitable?

Do analysts prefer AMPH or BEAM?

Do insiders and institutionals have more ownership in AMPH or BEAM?

Which has more volatility and risk, AMPH or BEAM?

Which has stronger valuation and earnings, AMPH or BEAM?

Does the media refer more to AMPH or BEAM?

Summary

How does Amphastar Pharmaceuticals compare to Dyne Therapeutics?

Which has more volatility and risk, DYN or AMPH?

Does the media prefer DYN or AMPH?

Do analysts rate DYN or AMPH?

Do insiders & institutionals believe in DYN or AMPH?

Is DYN or AMPH more profitable?

Which has preferable valuation & earnings, DYN or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Relay Therapeutics?

Does the media favor RLAY or AMPH?

Do institutionals and insiders believe in RLAY or AMPH?

Is RLAY or AMPH more profitable?

Which has stronger valuation and earnings, RLAY or AMPH?

Do analysts rate RLAY or AMPH?

Which has more risk & volatility, RLAY or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Does the media favor AMPH or ARQT?

Which has more volatility and risk, AMPH or ARQT?

Do institutionals & insiders believe in AMPH or ARQT?

Which has higher valuation and earnings, AMPH or ARQT?

Is AMPH or ARQT more profitable?

Do analysts rate AMPH or ARQT?

Summary

How does Amphastar Pharmaceuticals compare to Structure Therapeutics?

Is AMPH or GPCR more profitable?

Do institutionals & insiders believe in AMPH or GPCR?

Does the media refer more to AMPH or GPCR?

Which has more risk & volatility, AMPH or GPCR?

Which has preferable earnings and valuation, AMPH or GPCR?

Do analysts prefer AMPH or GPCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools